RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Gilead Sciences Stock

Gilead Sciences EBIT 2024

Gilead Sciences EBIT

7.5 B USD

Ticker

GILD

ISIN

US3755581036

WKN

885823

In 2024, Gilead Sciences's EBIT was 7.5 B USD, a -23.97% increase from the 9.86 B USD EBIT recorded in the previous year.

The Gilead Sciences EBIT history

YEAREBIT (undefined USD)
2029e-
2028e13.36
2027e12.75
2026e12.47
2025e11.9
2024e7.5
20239.86
202210.03
20219.92
20204.07
20194.46
20188.37
201714.39
201618.47
201522.19
201415.38
20134.59
20124.01
20113.86
20104.14
20093.59
20082.69
20072.17
20061.64
20051.11
20040.63

Gilead Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Gilead Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Gilead Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Gilead Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Gilead Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Gilead Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Gilead Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Gilead Sciences’s growth potential.

Gilead Sciences Revenue, EBIT and net profit per share

DateGilead Sciences RevenueGilead Sciences EBITGilead Sciences Net Income
2029e31.85 B undefined0 undefined11.14 B undefined
2028e31.05 B undefined13.36 B undefined10.51 B undefined
2027e30.14 B undefined12.75 B undefined9.96 B undefined
2026e29.39 B undefined12.47 B undefined9.71 B undefined
2025e28.51 B undefined11.9 B undefined9.12 B undefined
2024e28.26 B undefined7.5 B undefined4.86 B undefined
202327.12 B undefined9.86 B undefined5.67 B undefined
202227.28 B undefined10.03 B undefined4.59 B undefined
202127.31 B undefined9.92 B undefined6.23 B undefined
202024.69 B undefined4.07 B undefined123 M undefined
201922.45 B undefined4.46 B undefined5.39 B undefined
201822.13 B undefined8.37 B undefined5.46 B undefined
201726.11 B undefined14.39 B undefined4.63 B undefined
201630.39 B undefined18.47 B undefined13.5 B undefined
201532.64 B undefined22.19 B undefined18.11 B undefined
201424.89 B undefined15.38 B undefined12.1 B undefined
201311.2 B undefined4.59 B undefined3.08 B undefined
20129.7 B undefined4.01 B undefined2.59 B undefined
20118.39 B undefined3.86 B undefined2.8 B undefined
20107.95 B undefined4.14 B undefined2.9 B undefined
20097.01 B undefined3.59 B undefined2.64 B undefined
20085.34 B undefined2.69 B undefined1.98 B undefined
20074.23 B undefined2.17 B undefined1.59 B undefined
20063.03 B undefined1.64 B undefined-1.19 B undefined
20052.03 B undefined1.11 B undefined814 M undefined
20041.33 B undefined627 M undefined449 M undefined

Gilead Sciences stock margins

The Gilead Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gilead Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gilead Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Gilead Sciences's sales revenue. A higher gross margin percentage indicates that the Gilead Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Gilead Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Gilead Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Gilead Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Gilead Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Gilead Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Gilead Sciences Margin History

Gilead Sciences Gross marginGilead Sciences Profit marginGilead Sciences EBIT marginGilead Sciences Profit margin
2029e77.8 %0 %34.96 %
2028e77.8 %43.03 %33.85 %
2027e77.8 %42.3 %33.06 %
2026e77.8 %42.44 %33.05 %
2025e77.8 %41.74 %31.99 %
2024e77.8 %26.53 %17.2 %
202377.8 %36.37 %20.89 %
202279.26 %36.77 %16.83 %
202175.82 %36.32 %22.8 %
202081.48 %16.49 %0.5 %
201979.18 %19.86 %23.99 %
201878.07 %37.84 %24.65 %
201783.26 %55.13 %17.73 %
201685.98 %60.76 %44.43 %
201587.73 %67.98 %55.48 %
201484.78 %61.8 %48.62 %
201374.48 %40.99 %27.45 %
201274.52 %41.33 %26.71 %
201174.67 %46.08 %33.44 %
201076.49 %52.06 %36.5 %
200977.25 %51.19 %37.6 %
200878.88 %50.41 %37.09 %
200781.82 %51.18 %37.47 %
200685.69 %54.03 %-39.33 %
200587.18 %54.78 %40.14 %
200487.4 %47.32 %33.89 %

Gilead Sciences Aktienanalyse

What does Gilead Sciences do?

Gilead Sciences Inc, also known as Gilead, is an American biopharmaceutical company specializing in the development and production of drugs. It was founded in 1987 by Michael Riordan and has since become one of the largest biopharmaceutical companies in the world. Gilead focuses on developing drugs for difficult-to-treat diseases such as HIV, hepatitis, cancer, and inflammatory diseases. Its business model is divided into three segments: HIV, liver diseases, and oncology. The company has made significant advancements in antiviral therapies and aims to improve patients' lives and cure diseases through the development of new medical products and therapies. In the HIV segment, Gilead offers drugs such as Truvada, Atripla, and Biktarvy. In liver diseases, the company has focused on fighting hepatitis C and offers drugs like Harvoni, Sovaldi, and Epclusa. In the field of oncology, Gilead develops drugs for cancer treatment, particularly targeting specific mutations. The company has made notable progress in this area, such as developing the first approved CAR-T-cell therapy for lymphoma treatment, Yescarta. Gilead has also gained attention through its innovative research and development work, including licensing the CRISPR-Cas9 technology for targeted gene editing. Overall, Gilead Sciences Inc has had a remarkable success story and is considered one of the most significant biopharmaceutical companies globally, setting standards and bringing hope for cure to many people with serious illnesses. Gilead Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Gilead Sciences revenue by segment

In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % innovative Medicines

EBIT Details

Analyzing Gilead Sciences's EBIT

Gilead Sciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Gilead Sciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Gilead Sciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Gilead Sciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Gilead Sciences stock

How much did Gilead Sciences achieve in EBIT for the current year?

In the current year, Gilead Sciences has achieved an EBIT of 7.5 B USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Gilead Sciences.

How has the EBIT of Gilead Sciences developed in recent years?

The EBIT of Gilead Sciences has increased by -23.971% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Gilead Sciences?

The EBIT of Gilead Sciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Gilead Sciences pay?

Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 3.79 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.

What is the dividend yield of Gilead Sciences?

The current dividend yield of Gilead Sciences is 3.79 %.

When does Gilead Sciences pay dividends?

Gilead Sciences pays a quarterly dividend. This is distributed in the months of January, April, July, October.

How secure is the dividend of Gilead Sciences?

Gilead Sciences paid dividends every year for the past 15 years.

What is the dividend of Gilead Sciences?

For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.8 %.

In which sector is Gilead Sciences located?

Gilead Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gilead Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gilead Sciences from 9/27/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Gilead Sciences pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Gilead Sciences in the year 2023?

In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.

In which currency does Gilead Sciences pay out the dividend?

The dividends of Gilead Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Gilead Sciences

Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.